

8th annual World Cancer Series: Europe 2022

November 8th-9th 2022 * Marriott Hotel Grand Place, Brussels

Equitable access to outcome, innovation and excellence

Draft agenda—subject to change

Day 1: November 8th 2022

Day 1 opening remarks

Vivek Muthu, healthcare chair, Economist Impact

Keynote address - Collaborating and committing to innovation, equity and excellence in cancer care cross Europe

Panel: Innovation and excellence in cancer care—the priorities for Europe

How can inequalities be resolved in all aspects of cancer control including prevention, diagnosis, treatment and care? What are the most significant innovations and how can their development and adoption be accelerated? What policies and actions are the European Union and European Commission taking within Europe's Beating Cancer Plan and its associated activities to bring about innovation, equity and excellence? How are countries working to achieve the goals?

Interview: Inequalities in cancer control—facts and data

This session will provide the data on inequality of outcomes, alongside the differences in diagnosis rates, time to diagnosis, and how care is provided within countries and across Europe.

Panel: The future of European cancer control in a time of crisis

How do the pandemic, war in Ukraine, and economic pressures from inflation, sanctions and more defence spending affect the control of cancer and the EU's response? These could mean profound financial pressures and—owing to a possible decline in living standards across Europe—an increase in the burden of cancer. There is also the challenge of cancer control and care among people who are displaced or in conflict zones. Yet as covid-19 has shown, crises can stimulate innovation and collaborative problem-solving. How can innovation, equity in cancer control and access to optimal cancer care happen amid these challenges? Under

these conditions, what kind of cancer-control is realistic? What will the situation look like for patients, governments and industry within the next five years?

Networking break

Track 1: Prevention, early detection and diagnosis

Panel discussion: Stepping up prevention—the foundation of cancer control

This session will examine the preventive strategies in the Beating Cancer Plan and the specific interventions that are planned at an EU and country level. Do the measures go far enough? What stands in the way of their implementation? Speakers will highlight good examples of prevention and also show where progress is poor and why. What roles will personalised, preventative health and digital tools play? What strategies are being used to reach vulnerable and underserved populations?

Panel: Increasing the speed, accessibility and effectiveness of screening

This session will examine the role of cancer screening in the Beating Cancer Plan and how member states are progressing with those recommendations. Speakers will discuss inequalities in screening between and within countries, and ways they can be reduced. How can screening programmes yield a net benefit, especially in the face of rapid advances in diagnostic technologies?

Track 2: Accelerating innovation

Presentation: Incentivising innovation

This session will define innovation in cancer control and identify how to create the right incentives for it. What are the pathways for investment in innovation? Where is there a need for involvement from capital markets and public-private partnerships? How should success be rewarded?

Panel: Mobilising investment to create better outcomes for cancer patients

Cancer control is a priority for Europe. What investments are being made at a European level by the public and private sectors? Where are there gaps and how are they being overcome? How can innovative research and start-ups attract investment and move to operating at scale?

Lunch

Interview: The importance of early diagnosis

Late diagnosis of cancer is a major cause of preventable suffering and death across the continent. It also increases the cost of care. Time to diagnosis is a major sphere of inequity across European countries. What will it take to equitably reduce time to diagnosis? Are there examples of good practice and rapid improvement in diagnosis time from which others can learn?

Presentation: The patient's role in driving innovation

The patient's voice is critical at every step of the cancer journey. This session will highlight the importance of involving patient advocates in the early stages of clinical studies, when there is a particular opportunity for them to make a difference.

Presentation: The future of diagnostics

This session will provide an overview of new technologies and methods for cancer control

Interview: Biotech—a comparison with America

This interview will compare the biotech landscape in Europe and America. Where can improvements be made

and diagnostics, exploring where their effects on patient care will be felt most in the next decade and how they can contribute to equity and excellence.	to foster a more vibrant and efficient cancer innovation ecosystem in Europe? What are the biggest opportunities for collaboration between Europe and America?
Panel: Which novel biomarkers are changing patient outcomes? Novel biomarkers have the potential to transform patient outcomes through early diagnosis and the development of personalised treatment plans. Which biomarkers are making the most impact? Where is the greatest potential for advancements, and how can access to tests be improved?	Presentation: Workforce and service-delivery innovation The pandemic has taken a huge physical and mental toll on the healthcare workforce. As outbreaks continue, exhausted workers are left dealing with the trauma of their frontline experience while catching up on a backlog of medical care, all amid staff shortages. What solutions are in place to keep staff motivated, supported and able to continue in delivering quality care? Could artificial intelligence and other technologies lighten the load?
Break	Break
Interview: Could liquid biopsy transform cancer detection? Non-invasive diagnosis of cancer has clear advantages, including reduced risk and pain. What is its potential to catch cancer before symptoms appear and to improve progression and survival rates? What are the next steps to increase the efficacy and accessibility of liquid biopsies?	Panel: Harnessing the power of real-world data to speed innovation How can real-world data and evidence increase the rate at which innovations translate into better care? Speakers will discuss not only the role of data in R&D, but also how it can help with better service delivery and improvements in quality, safety, effectiveness and equity along the entire care continuum. What are examples of empirical evidence being used in these ways? How should the public and private sectors partner in using data to hasten innovation?
Panel: Moving genomics up the priority list What role could genomics play in delivering a diagnostic service centred on innovation, equity and excellence? How can it be moved up the list of priorities for improving accessibility across Europe? How can challenges around data-sharing be managed?	Panel: Development, regulation and access—pathways to faster innovation How are regulators, health-technology assessment bodies and payers working with innovators to deliver fast, safe, high-value and cost-effective innovation that will improve cancer control, while guarding against the temptation to engage in innovation for innovation's sake?
Day 2: November 9th 2022	
Breakfast spotlight sessions This is a new section in the World Cancer Series. Over the course of our upcoming conferences, we will schedule spotlight sessions that focus on a particular cancer type, explore how it is being tackled across Europe, and note what it will take to reduce risk and improve outcomes. In this conference, two sessions will run concurrently: Spotlight 1: Lung cancer in Europe Spotlight 2: Breast cancer in Europe	
Day 2 Opening remarks from the chair	

Panel: Enhancing efficiency in cancer care

Resources are always limited. Optimal cancer control and care demand that these resources are deployed in the most effective way to deliver outcomes for patients. Any discussion about better cancer control must not only assess the impact of innovation and greater investment, but also consider how to better deploy existing technologies, resources and capital. Evidence suggests that there is massive scope to improve the efficiency of cancer control and that large gains can be readily achieved.

In this session, panelists will discuss, by looking at specific examples, what can be done for patients, providers and payers to boost efficiency. It will also cover how efforts at improving efficiency can be scaled.

Panel: Addressing gaps in supportive care

This section of the conference focuses on care that extends beyond interventions to diagnose and treat cancer, including broader support for patients and their families. Surveys of those experiencing cancer care universally say that wider supportive care is often lacking and represents a huge need that is served inequitably. What examples of good practice can be scaled up? What can be done to improve supportive services and who can provide them?

Interview: What does good end-of-life care look like?

Like supportive care, high quality end-of-life care represents a critical need that is often underserved, despite its importance for patients and their loved ones. Here we discuss what good end-of-life care looks like, and how to ensure that, in our enthusiasm for innovative treatments, we do not neglect the reality that for some people, end-of-life care is the only option and must be adequately resourced, and effectively and equitably accessible.

Networking break**Track 1: Frontiers in treatment****Track 2: AI, data and digital healthcare for cancer****Interview: Assessing new approaches in cancer therapy**

This session will assess breakthrough treatments and ask what the future of cancer therapy looks like, with a focus on access and excellence.

Presentation: Could AI transform cancer diagnosis and care?

AI has the power to transform cancer diagnosis and treatment, and to make patient care better. By automating processes, could AI also make treatment and diagnosis radically more accessible? This presentation will assess the power of AI to boost innovation in cancer care.

Panel: Making precision medicines a reality

Advances in genomically-targeted precision medicines are set to reshape cancer care. What does genomics promise for the future of cancer care? Speakers will consider the economics and logistics of getting personalised treatments to market in good time and at a lower cost.

Panel: Putting AI and data to work in R&D

This session considers the role of AI, data and technology to speed up drug discovery. What new avenues for R&D have been opened by the exponential increases in computation? What have been the successes, how have they been achieved and can they be scaled? What are the EU and the European Medicines Agency doing to facilitate AI-driven R&D, and what are the difficulties involved? What datasets need to be used by AI for R&D and what are the hurdles to obtain and use them?

Lunch**Interview: Redesigning cancer treatment with radioligand therapy**

Radioligand therapy uses nuclear medicine to

Panel: Digitising care delivery

Speakers will discuss how data and digital technologies can enhance care delivery. What are the most promising

<p>target and treat cancer cells with precision. Where does the potential lie for radioligand therapy to improve cancer care? What are the barriers to universal access and the steps to achieving equity?</p>	<p>uses? How can cancer data-silos be combined to better harness the information they contain? What data-sharing is needed across providers and between the public sector and innovators? What role should tech companies play in collecting and using medical data? How can regulation and governance be established to safely harness the benefits of using data to improve care?</p>
<p>Panel: Improving outcomes through advances in radiotherapy How are cutting-edge developments in radiotherapy improving patient outcomes, and what is needed to ensure quality and equity of access? Which solutions may reduce the post-covid backlog? How are digital technologies supporting the development of speed and efficiency?</p>	<p>Presentation: How could digital technologies change patient journeys? This session will outline the potential effects of digital technologies at every step of the patient journey. How can digital healthcare give patients additional support and reassurance?</p>
<p>Panel: The future of immunotherapies, including CAR-T Immunotherapies, including CAR-T cell therapy, are a focus for innovation, and offer the promise of better outcomes. What impact have these therapies had to date? What improvements in investment, infrastructure and access are needed to realise widespread benefits?</p>	<p>Interview: Does technology hold the key to improving efficiency, effectiveness and equity? Could AI, the internet of things and other technologies overcome current roadblocks to make cancer control and care more effective? What is needed to ensure their safe and equitable implementation?</p>
<p>Interview: Accelerating vaccine development How is the development of cancer vaccines progressing? Are there lessons from the creation of covid-19 vaccines? How could therapeutic cancer vaccines equitably improve outcomes across Europe?</p>	
<p>Closing panel: The future of cancer care</p>	